Haptoglobin and sickle cell polymorphisms and risk of active trachoma in Gambian children. by Savy, Mathilde et al.
Savy, M; Hennig, BJ; Doherty, CP; Fulford, AJ; Bailey, R; Holland,
MJ; Sirugo, G; Rockett, KA; Kwiatkowski, DP; Prentice, AM; Cox,
SE (2010) Haptoglobin and sickle cell polymorphisms and risk of ac-
tive trachoma in gambian children. PloS one, 5 (6). e11075. ISSN
1932-6203 DOI: https://doi.org/10.1371/journal.pone.0011075
Downloaded from: http://researchonline.lshtm.ac.uk/3425/
DOI: 10.1371/journal.pone.0011075
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Haptoglobin and Sickle Cell Polymorphisms and Risk of
Active Trachoma in Gambian Children
Mathilde Savy1, Branwen J. Hennig1, Conor P. Doherty2, Anthony J. Fulford1, Robin Bailey2,3, Martin J.
Holland2,3, Giorgio Sirugo2,4, Kirk A. Rockett5, Dominic P. Kwiatkowski5,6, AndrewM. Prentice1, Sharon E.
Cox1*
1MRC International Nutrition Group, London School of Hygiene & Tropical Medicine, London, United Kingdom, 2MRC Laboratories, Fajara, The Gambia, 3Department of
Infectious Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom, 4Department of Medical Genetics, San Pietro Hospital, Rome, Italy,
5Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom, 6Malaria Programme, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Abstract
Background: Susceptibility and resistance to trachoma, the leading infectious cause of blindness, have been associated with
a range of host genetic factors. In vitro studies of the causative organism, Chlamydia trachomatis, demonstrate that iron
availability regulates its growth, suggesting that host genes involved in regulating iron status and/or availability may
modulate the risk of trachoma. The objective was to investigate whether haptoglobin (Hp) haplotypes constructed from the
functional polymorphism (Hp1/Hp2) plus the functional promoter SNPs -61A-C (rs5471) and -101C-G (rs5470), or sickle cell
trait (HbAS, rs334) were associated with risk of active trachoma when stratified by age and sex, in rural Gambian children.
Methodology and Principal Findings: In two cross sectional surveys of children aged 6–78 months (n = 836), the prevalence
of the clinical signs of active trachoma was 21.4%. Within boys, haplotype E (-101G, -61A, Hp1), containing the variant allele
of the -101C-G promoter SNP, was associated with a two-fold increased risk of active trachoma (OR= 2.0 [1.17–3.44]). Within
girls, an opposite association was non-significant (OR= 0.58 [0.32–1.04]; P = 0.07) and the interaction by sex was statistically
significant (P = 0.001). There was no association between trachoma and HbAS.
Conclusions: These data indicate that genetic variation in Hp may affect susceptibility to active trachoma differentially by
sex in The Gambia.
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Introduction
Trachoma, a chronic keratoconjunctivitis caused by the
intracellular bacterium Chlamydia trachomatis, is the leading
infectious cause of blindness worldwide [1]. Repeated episodes
of infection cause intense conjunctival inflammation (active
trachoma), which can lead to chronic infection and conjunctival
scarring, corneal scarring, opacification and, ultimately, blindness
[2]. Trachoma disease progression is variable and incidence varies
by age and sex [3,4]. Some individuals experience prolonged
infection, while others clear their infections in a few weeks.
Differences in the inflammatory response to infection have been
proposed as a determinant of progressive disease [5,6,7]. Although
interventions have considerably reduced the number of people
with blinding trachoma over the past decades, current estimates
indicate that active trachoma still affects some 80 million people
worldwide and about 8 million people are visually impaired [8].
Host genetic factors play a major role in susceptibility or
resistance to many infectious diseases [9,10], including C.
trachomatis [11,12]. Genetic association studies so far, have focussed
on trachoma scarring or trachomatous trichiasis and human
polymorphisms within loci involved in immunity and inflamma-
tion [13] and include several within the TNF locus including the -
308G-A TNF-a promoter single nucleotide polymorphism (SNP)
[14,15]; the -1082A-G IL-10 SNP [16,17]; chemokine and
cytokine clusters in chromosomes 4q & 5q31 and HLA class I
alleles [18], reviewed in [12]. Active trachoma in Gambian
children has also been associated with the IL-10 -3917-G allele
[19]. Acquisition of iron is a fundamental step in the development
of a pathogen within its host. Evidence from in vitro studies suggests
that low iron availability leads to impaired growth and infectivity
of C. trachomatis [20,21] but may also contribute to persistence or
re-activation of dormant infection [20,22,23], whilst the anti-
chlamydial action of some compounds is reversed in the presence
of an iron source including holo-transferrin [24]. The accumula-
tion of transferrin and its receptors around chlamydial inclusions
in low-iron environments may suggest the mechanism of iron
acquisition by C. trachomatis [20,25]. In combination these and
other studies suggest that variation in host genes involved in
modulating immune, particularly inflammatory type responses and
in regulating iron status and/or iron availability may affect the
outcome of trachoma infection.
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Haptoglobin (Hp), an acute phase protein, encoded by two major
co-dominant alleles, Hp1 and Hp2, results in three functionally
distinct phenotypes, Hp11, Hp12 and Hp22. Promoter polymor-
phisms -61A-C (rs5471) and -101C-G (rs5470) have been associated
with ahaptoglobinaemia and hypohaptoglobinaemia, respectively
[26], whilst reporter gene assays also demonstrated that -61C
promoter constructs had significantly decreased transcriptional
activity [27]. Haptoglobin binds circulating, toxic, free hemoglobin
(Hb) released during intravascular haemolysis – such as occurs
during malarial infections. The resultant complex is taken up by
CD163 on circulating monocytes and macrophages leading both to
an altered cytokine secretory profile [28,29] and the eventual
recycling of the iron component of haem for erythropoiesis. Plasma
concentrations of haptoglobin, and the binding affinities of Hp for
free hemoglobin and of the Hp-Hb complex for CD163 vary by
phenotype. Hp22 has been associated with evidence of increased
oxidant stress and iron delocalisation [30,31,32], as well as an
increased risk of malaria-associated anemia [33,34]. Hp is also
thought to affect immune regulation, including the balance of
Th1:Th2 cytokine responses [35] and several studies have
associated haptoglobin phenotypes and genotypes with a range of
conditions including cardiovascular disease [36], diabetes [37,38],
HIV infection [39,40,41] and susceptibility to malaria [42,43,44,45]
including a protective association of the Hp haplotype containing
the Hp2 and the C allele for the promoter -61A-C (rs5471) SNP in
Gambian children [46]. A protective effect of the genetic variant
sickle cell trait (HbAS) against malaria has been well documented
[47,48,49,50,51]. However, few studies have assessed whether
HbAS may be protective against other conditions [50]. There is
evidence that alpha thalasaemia, which is protective against severe
malaria, is also protective against severe morbidity from other
infections, perhaps due to an interaction betweenmalaria and risk of
other infections [52].
Therefore we investigated whether Hp haplotypes constructed
from the functional Hp allele (Hp1 or Hp2) plus the functional
promoter SNPs -61A-C (rs5471) and -101C-G (rs5470) and HbAS
were associated with the risk of active trachoma in Gambian children.
Methods
Design and sampling
Two cross sectional surveys of clinical signs of acute trachoma of
children aged 6–78 months were conducted in September 2003 &
January 2005 in eight rural Mandinka villages in the West Kiang
district of The Gambia. As some children were visited in both
years and others only once, only the first visit of each child was
considered in the analysis. Children known to have sickle cell
disease (HbSS) (n = 4) were excluded from analysis.
Grading of Chlamydia trachomatis infection
Clinical signs of active trachoma were assessed using a 62
binocular loupe and pen torch by single grader. Both eyelids were
everted and scored according to the WHO simplified trachoma
grading system [53]. Active trachoma was defined as the presence of
grades TF (follicular trachoma) or TI (intense inflammatory
trachoma) in one or both eyes, with the eye with the greatest clinical
severity being used for the outcome result. Eight children were found
to have trachomatous scarring (TS) but none with trichiasis (TT).
These eight children were excluded from the current analysis for risk
of active trachoma. All children with active trachoma were offered
treatment with tetracycline eye ointment as per Gambian national
eye care programme guidelines at the time. Finally, following further
structured surveys as part of a national programme [54], these
communities were treated with 3 annual rounds of oral azithromy-
cin, completed in 2009 as per WHO and the International Council
of Ophthalmology guidelines for community control strategies.
Genotyping and haplotype construction
DNA was extracted from peripheral blood leukocytes using a
standard salting out method [55]. Aliquots of DNA were shipped
to the Wellcome Trust Centre for Human Genetics, Oxford, UK,
where all genotyping was conducted. Haptoglobin was genotyped
by allele-specific PCR adapted from a method published by Koch
et al. [56]. This method determines the Hp1 and Hp2 alleles but
does not distinguish between the ‘‘F’’ and ‘‘S’’ subtypes of the Hp1
and Hp2 alleles. It therefore avoids potential misclassification
based on the presence of these sub-types in different populations
[57]. PCR products were resolved by agarose gel electrophoresis
and visualised under UV light. Details of primers and cycling
conditions are provided in the supplementary material (Table S1).
SequenomH MassARRAYH (SequenomH, Hamburg Germany)
was used to genotype the haptoglobin promoter -61A-C (rs5471),
-101C-G (rs5470) SNPs and HbS (rs334: hemoglobin – sickle)
according to manufacturer’s instructions.
Genotyping accuracy was verified by sequencing (eurofins
MWG operon) in both directions in 56 samples with different Hp
haplotypes. PCR products for sequencing were generated using
primers Hp-Ex-U (59-GCA GTG TGA AAA TCC TCC AAG
ATA A-39) and Hp-Ex1-L (59-AAT TTA GCC CAT TTG CCC
GTT TCT T-39) under standard conditions.
Haplotypes for the two Hp promoter SNPs and the Hp gene
alleles (Hp1 and Hp2) were constructed using SNPHAP [58].
Ethical permission
The study was approved by the joint Medical Research
Council/Gambian Government Ethics Committee. The Gambian
National DNA Collection Guidelines were followed regarding the
handling of genetic material and information [59]. Parental
written informed consent was obtained for all study participants.
Data analyses
Data analyses were performed using SAS version 9.1 (SAS
Institute, Cary NC, USA). Differences in the prevalence of active
trachoma between villages and by age (in years) and sex of
children were tested using logistic regression. We have previously
observed age-dependent effects of Hp variation on malaria risk
[46] [45] within a sub-set of these children, whilst iron status can
differ by sex in young children [60]. Therefore we analysed
associations between genotypes and active trachoma using logistic
regression models stratified by age group (greater or less than the
median age of 36 months, to reduce the number of groups tested
and increase precision of the estimates of effect) and by sex, and
subsequently tested for interactions by comparison of models with
and without inclusion of the interaction terms gene*age (greater or
less than 36 months) or gene*sex in models. Village was included
in all models a priori, whilst in models stratified by age, sex was
included a priori and age (in years) was included a priori in models
stratified by sex. Hp haplotypes were fitted as categorical variable
with 0, 1 or 2 copies. As children who were found to be HbSS
were excluded from analyses, sickle genotype was fitted as a simple
binary variable (HbAS vs. HbAA).
Results
Demographic and genetic characteristics of study
subjects
A total of 1155 children were examined for clinical signs of
trachoma. Of these, 235 (20.3%) had active trachoma, 11 (0.95%)
Gene Polymorphisms & Trachoma
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had signs of trachomatous inflammation (TI) and 8 (0.69%) with
trachomatous scarring (TS). There was no evidence of a difference
by sex (Table 1). DNA samples were available from 1089 of these
children. Complete genetic, clinical and socio-demographic data
were available for 836 children with complete Hp haplotypes, and
for 807 children screened for HbS and were included in the
current analyses. The mean age of children included in the
analysis was 35.6618.1 months. The distribution of covariates and
Table 1. Characteristics of the study population.
n
Children included
in the analysis [%] n
Children not included
in the analysis [%]a P-value
Sociodemographic variables
Age (month) 836 282
,= 36 54.1 52.1 NS
.36 45.9 47.9
Age (year) 836 282
1 35.4 34.7 NS
2 18.4 17.4
3 17.7 15.6
4 15.4 14.2
5 13.0 18.1
Sex 836 317
male 50.4 51.1 NS
female 49.6 48.9
Village 836 317
a 10.0 7.3 0.01
b 11.7 12.0
c 23.3 15.8
d 8.8 10.4
e 12.9 11.7
f 12.4 18.6
g 9.0 8.5
h 11.7 15.8
Genotype distribution
No of copies of Hp2 allele 836 61
0 20.9 21.3 NS
1 58.0 59.0
2 21.1 19.7
-101C-G 836 162
CC 73.2 71.0 NS
CG 25.4 25.3
GG 1.4 3.7
-61A-C 836 161
AA 74.8 83.2 0.02
AC 25.2 16.8
CC 0.0 0.0
HbS 807 177
HbAA 82.0 86.4 NS
HbAS 18.0 13.7
Trachoma status
Active trachomaa 836 317
Yes 21.4 17.7 NS
No 78.6 82.3
aOut of the 1155 children who had trachoma assessment, 836 children were included in the final analyses and 319 were not (because of missing data or because they
were found to have sickle cell disease (HbSS), trachomatous scarring (TS) or protein-energy malnutrition as determined by weight-for-height z-score,23 SD). In the
836 individuals included HWE p-values were ,0.0001; 0.184, and ,0.0001 for Hp1/2, -101C-G, and -61A-C, respectively.
doi:10.1371/journal.pone.0011075.t001
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genotypes for children included in the analysis versus those not
included is presented in Table 1. With the exception of village of
residence (P= 0.01) there were no statistically significant difference
in the distribution of covariates between the included/excluded
groups, including the prevalence of active trachoma. There were
no differences in the distribution of genotypes between the two
groups, except for the Hp-61A-C promoter SNP for which fewer
AA homozygotes and more heterozygotes were detected in the
children included in the analysis (P = 0.02). Genotype frequencies
did not differ by village of residence, except for HbAS (P= 0.0004)
(data not shown).
Genotypes were not in Hardy Weinberg equilibrium (Table 1)
for Hp1/2 as well as the -61A-C polymorphism, for which, as
previously reported [46], no CC homozygotes were detected.
Sequencing 56 samples in both directions confirmed the absence
of -61C-C homozygotes and genotypes determined by sequencing
correlated 100% with those determined by hME Sequenom typing
for both Hp promoter SNPs.
Four common (frequency .10%) and two less common
(frequency #1%) Hp haplotypes were detected (Table 2). As
previously reported [26] the variant -61C allele appeared much
more frequently in conjunction with the Hp2 allele (haplotype D),
whilst the -101G allele was found more often with the Hp1 allele
(haplotype E). No haplotypes containing the variant alleles for
both of the promoter SNPs were detected.
Associations between active trachoma and haptoglobin
haplotypes and sickle cell trait
The prevalence of active trachoma did not vary by age or sex of
the study participants, but did by village of residence, ranging from
7.1 to 34.7% (P=0.0004) (Table 3).
When stratified by sex. The Hp haplotype E (-101G, -61A,
Hp1), containing the variant allele of the -101C-G promoter SNP,
was associated with a two-fold increased risk of active trachoma in
boys, but with a non-significantly decreased risk in girls (P = 0.07)
(Table 4). This interaction was statistically significant (P = 0.001).
There was no evidence of an association of the prevalence of active
trachoma with the other Hp haplotypes or with HbAS vs HbAA,
in either sex or either age group (data not shown by age group).
Discussion
The prevalence of active trachoma was high, an average of
20%, compared to 6% in a smaller survey of 140 children aged 1–
9 years in West Kiang District, conducted in 2006 [54]. The
prevalence of active trachoma varied significantly by village,
similar to other observations in The Gambia [54]. We did not find
any difference in the rate of active trachoma between age groups
or sex, contrary to some reports in which older children (3–5 years
old) and females are more likely to have trachoma [3,4]. However,
it is unclear how much of previously observed sex and age
differences relate to inherent responses to infection or to cultural
practices leading to differences in exposure [4].
Here we report a sex-specific effect of the Hp haplotype E (-
101G, -61A, Hp1) and susceptibility to active trachoma in
Gambian children. The small number of individuals with two
copies of the Hp haplotype E did not allow us to assess whether
there might be a dose effect of carriage of this haplotype on risk of
trachoma. In 257 Gambian children with no malaria infection,
Table 2. Prevalence of haplotypes constructed from main haptoglobin alleles (Hp1 and Hp2) and Hp promoter SNPs -101C-G
(rs5470) and-61A-C (rs5471).
Haplotype -101C-G (rs5470) -61A-C (rs5471) Hp Haplotype frequency (n =2*836) Copy number of haplotypes N=836, n (%)
0 1 2
A C A 1 36% 321 (38.4) 431 (51.5) 84 (10.0)
B C A 2 37% 319 (38.2) 408 (48.8) 109 (13.0)
C C C 1 0.5% 832 (99.5) 4 (0.5) 0 (0.0)
D C C 2 12% 629 (75.2) 207 (24.7) 0 (0.0)
E G A 1 14% 614 (73.4) 212 (25.4) 10 (1.2)
F G A 2 0.5% 832 (99.5) 4 (0.4) 0 (0.0)
doi:10.1371/journal.pone.0011075.t002
Table 3. Active trachoma as a function of children age, sex
and village of residence included in the current analysis
(n = 836).
n
Active
Trachoma (%) OR [CI] P-value
Age (mo)
,= 36 452 21.0 1.0 NS
.36 384 21.9 1.05 [0.75–1.46]
Age (year)
1 296 18.6 1.0 NS
2 154 25.3 1.49 [0.93–2.37]
3 148 25.0 1.46 [0.90–2.34]
4 129 19.4 1.05 [0.62–1.78]
5 109 21.1 1.17 [0.68–2.02]
Sex
female 421 22.1 1.0 NS
male 415 20.7 0.92 [0.66–1.28]
Village
a 84 7.1 1.0 0.0004
b 98 19.4 3.13 [1.18–8.24]
c 195 23.1 3.90 [1.59–9.54]
d 74 16.2 2.52 [ 0.89–7.08]
e 108 25.9 4.55 [1.78–11.59]
f 104 15.4 2.36 [0.88–6.34]
g 75 25.3 4.41 [ 1.65–11.75]
h 98 34.7 6.91 [ 2.73–17.48]
doi:10.1371/journal.pone.0011075.t003
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haplotype E (-101G, -61A, Hp1) was highly associated with a
decreased risk of having non-detectable levels of plasma Hp
(OR=0.41, p = 0.002) [46]. It is possible that an effect of this Hp
haplotype on risk of active trachoma is mediated though increased
levels of Hp and differential inflammatory responses from
interactions between Hp1 or Hp2 protein with macrophages
[35], T cells [61], or other immune-modulatory effects [62]
including possible effects on adaptive immunity [63]. We cannot
currently explain why the effects of this Hp haplotype differ by sex;
however, sex differences in disease patterns and in responses to
vaccination are well known, and it is increasingly recognised that
many immune functions may differ by sex even in young children
[64,65]. Sex specific effects of Hp phenotype and markers of iron
status have been documented in some [66], but not other studies
[67] for reasons that are not clear. Data on iron status was
available for a small number of individuals (N,250), preventing us
from carrying out meaningful analysis of possible interactions
between Hp haplotype and iron status.
As we have previously reported in a sub-set of this population
[46], we did not detect any C-C homozygotes for Hp -61A-C. To
confirm that the absence of -61C-C homozygotes was not due to
technical issues the accuracy of the genotyping method for the two
Hp promoter SNPs was confirmed by sequencing 56 samples,
selected to represent each haplotype. Indeed we have replicated
these results again employing another hME Sequenom assay
employing different primers taking into account two other
promoter polymorphisms in the same vicinity (rs5469 3bp from
-101C-G and rs5472 6pb from -61A-C; unpublished data, Rockett
& Cox). The distribution of the Hp haplotypes reported by
ourselves previously was confirmed in this larger sample [46],
whilst the associations between the promoter SNPs with the Hp1
& Hp2 alleles has also been previously reported in West Africans
from Ghana [26]. Similarly, publicly available data through the
National Center for Biotechnology Information (NCBI http://
www.ncbi.nlm.nih.gov/) indicates that -61C-C homozygotes are
not present in populations of Caucasian, Pacific RIM, Hispanic,
African American and African ancestry, with exception of the
Yoruba panel where 1 out of 24 individuals was found to be
homozygous for the C allele. This supports our earlier hypothesis
that this polymorphism is under some selection pressure (similar to
HbS), possibly from a deleterious effect of carriage of two copies of
the C allele, resulting in the absence of -61C-C homozygotes.
In summary, in a cohort of 836 children up to 6.5 years of age
across 8 villages in West Kiang The Gambia, the prevalence of
active trachoma was 21.4%. Our observation of an increased risk
of active trachoma in children with the Hp haplotype (-101G,
Table 4. Associations between active trachoma and haplotypes or genotypes by sex.
Females (n =421a) Males (n =415a) P-value interaction sex
n % OR [0.95 CI] n % OR [0.95 CI]
Haplotype (No of copies)
A
0 159 21.8 1.0 162 22.7 1.0 NS
1 216 19.1 0.84 [0.51–1.40] 215 15.4 0.62 [0.36–1.05]
2 46 20.7 0.93 [0.41–2.13] 38 21.5 0.93 [0.39–2.23]
P-value NS NS
B
0 169 18.5 1.0 150 19.3 1.0 NS
1 202 19.9 1.10 [0.64–1.85] 206 18.5 0.94 [0.55–1.62]
2 50 27.9 1.70 [0.80–3.61] 59 18.6 0.95 [0.44–2.07]
P-value NS NS
Db
0 312 18.6 1.0 317 19.6 1.0 NS
1 109 25.2 1.47 [0.86–2.51] 98 16.0 0.78 [0.42–1.44]
2 0 - - 0 - -
P-value NS NS
Eb
0 305 22.8 1.0 309 15.9 1.0 0.001
1 110 14.6 0.58 [0.32–1.04] 102 27.5 2.0 [1.17–3.44]
2 6 - - 4 - -
P-value 0.07 0.04
Genotype
HbAA 334 20.2 1.0 328 17.8 1.0 NS
HbAS 76 19.1 0.93 [0.49–1.75] 69 22.9 1.37 [0.71–2.64]
P-value NS NS
Analyses by sex are adjusted for age in years and village.
aexcept for the analysis with HbS where n= 410 for the girls only group, n = 397 for the boys only group.
bDue to small numbers individuals with 2 copies of these haplotypes were not included in the analysis.
doi:10.1371/journal.pone.0011075.t004
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-61A, Hp1), in boys, with a non-significant decreased risk in girls
and statistically significant interaction warrants further investiga-
tion of possible associations between Hp polymorphisms and
inflammatory, immune and infectious outcomes by sex.
Supporting Information
Table S1 Haptoglobin Hp1/Hp2 - PCR conditions and primer
sequences - method adapted from Koch et al. 2003.
Found at: doi:10.1371/journal.pone.0011075.s001 (0.05 MB
DOC)
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